Challenges and Emerging Opportunities for Targeting mTOR in Cancer.

Journal Article (Journal Article)

The mechanistic target of rapamycin (mTOR) plays a key role in normal and malignant cell growth. However, pharmacologic targeting of mTOR in cancer has shown little clinical benefit, in spite of aberrant hyperactivation of mTOR in most solid tumors. Here, we discuss possible reasons for the reduced clinical efficacy of mTOR inhibition and highlight lessons learned from recent combination clinical trials and approved indications of mTOR inhibitors in cancer. We also discuss how the emerging systems level understanding of mTOR signaling in cancer can be exploited for the clinical development of novel multimodal precision targeted therapies and immunotherapies aimed at achieving tumor remission.

Full Text

Duke Authors

Cited Authors

  • Wood, KC; Gutkind, JS

Published Date

  • November 2022

Published In

Volume / Issue

  • 82 / 21

Start / End Page

  • 3884 - 3887

PubMed ID

  • 36321262

Pubmed Central ID

  • PMC9634680

Electronic International Standard Serial Number (EISSN)

  • 1538-7445

International Standard Serial Number (ISSN)

  • 0008-5472

Digital Object Identifier (DOI)

  • 10.1158/0008-5472.can-22-0602


  • eng